Rilzabrutinib for blood disorder shows promise in phase 1--2 clinical trial

In an international phase 1--2 clinical trial of patients with immune thrombocytopenia, an oral investigational drug called rilzabrutinib was active and associated with only low-level toxic effects at all dose levels.